Tauopathy

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

Retrieved on: 
Martedì, Settembre 13, 2022
Tauopathy, FFI, Risk, Superoxide dismutase, Inflammation, Variant Creutzfeldt–Jakob disease, Memory, Human, FTD, Twitter, NYSE, Brain, AD, Hans Gerhard Creutzfeldt, FSE, BSE, EUE, Neurodegeneration, Parkinson's disease, LinkedIn, Company, GSS, CWD, Cognition, Stroke, Bovine spongiform encephalopathy, CTE, Forward-looking statement, U.S. Securities and Exchange Commission, Prion, Patient, CEO, Creutzfeldt–Jakob disease, Huntington's disease, Chronic traumatic encephalopathy, Annual report, TDP43, Scrapie, Toxicity, ALS, Security (finance), Pharmacokinetics, Chronic wasting disease, Frontotemporal dementia, PD, Gian Maria Annovi, TME, Patent, Axonal transport, Alzheimer's disease, CJD, Pharmaceutical industry, Vaccine, Huntingtin

The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.

Key Points: 
  • The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap.
  • A method of treating amyloid lateral sclerosis, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of superoxide dismutase protein1 and TDP43.
  • A method of treating Huntington's disease, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of Huntingtin protein.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy

Retrieved on: 
Martedì, Agosto 9, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Association, Principal, NIH, CEO, CNS, Palsy, National Institute, Frontotemporal dementia, National, Prevalence, Caregiver, Albert Einstein College of Medicine, Patient, Discovery, Twitter, Acceleration, Therapy, Outline of health sciences, Neurodegeneration, NIA, Safety, Research, AD, MBA, Tauopathy, LinkedIn, Pharmacokinetics, Pharmaceutical industry

Oligomerix plans to begin a Phase 1a clinical trial in healthy volunteers in 2022.

Key Points: 
  • Oligomerix plans to begin a Phase 1a clinical trial in healthy volunteers in 2022.
  • Based on our preliminary results, this oral small molecule, CNS drug-like lead significantly fulfills these requirements, said James Moe, Ph.D., MBA, CEO and Head of Discovery at Oligomerix.
  • We look forward to potentially bringing a new treatment option to the millions of patients suffering from AD and other neurodegenerative diseases.
  • Oligomerix is seeking strategic partners and investors to support the acceleration and advancement of these important programs.

Prothena Reports Second Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Lunedì, Agosto 8, 2022
U.S. Securities and Exchange Commission, Survival, FTD, Trial of the century, GLOBE, R, SEC, Clinical trial, Chronic traumatic encephalopathy, Security (finance), Research, Neurodegeneration, Fast track (FDA), Biology, Organ dysfunction, Disease, ISA, Epitope, TTR, CTE, AL, Alpha-synuclein, Tau, Confirmatory trial, PSP, Income, BMS, AD, Bristol Myers Squibb, Antibody, Novo Nordisk, PD, Frontotemporal dementia, ATTR, Company, Amyloid, Therapy, NASDAQ, Tauopathy, Pharmaceutical industry, Vaccine, Fine chemical, Video game, G&A, Amyloidosis, Patient

Prothena reported total revenue of $1.3 million and $2.5 million for the second quarter and first six months of 2022, respectively, primarily from collaboration revenue from BMS.

Key Points: 
  • Prothena reported total revenue of $1.3 million and $2.5 million for the second quarter and first six months of 2022, respectively, primarily from collaboration revenue from BMS.
  • Research and development (R&D) expenses totaled $31.6 million and $58.8 million for the second quarter and first six months of 2022, respectively, as compared to $21.1 million and $42.2 million for the second quarter and first six months of 2021, respectively.
  • General and administrative (G&A) expenses totaled $13.0 million and $24.8 million for the second quarter and first six months of 2022, respectively, as compared to $11.0 million and $22.2 million for the second quarter and first six months of 2021, respectively.
  • Total non-cash share-based compensation expense was $8.3 million and $15.9 million for the second quarter and first six months of 2022, respectively, as compared to $5.5 million and $11.7 million for the second quarter and first six months of 2021, respectively.

Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models

Retrieved on: 
Mercoledì, Agosto 3, 2022
Private Securities Litigation Reform Act, AAV, Inflammation, Mouse, COVID-19, Annual report, Senior, Capsid, Voyager, Pathology, Lists of diseases, Patient, Nasdaq, U.S. Securities and Exchange Commission, Palsy, Rapunzel's Tangled Adventure (season 2), Neurodegeneration, Tauopathy, Technology, Research, Antibody, Therapy, Frontotemporal dementia, GLOBE, Conference, Cerebrospinal fluid, Epitope, Muscle atrophy, Traffic barrier, Hippocampus, Vaccine

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data showing the use of novel antibodies targeting hyperphosphorylated forms of tau. Two therapeutic approaches were used to show that the spread of pathological tau can be impeded in rodent models: passive immunotherapy with novel antibodies and an intravenously delivered vectorized novel antibody using a blood-brain-barrier penetrating AAV capsid. The data were presented at the Alzheimer’s Association International Conference.

Key Points: 
  • Two therapeutic approaches were used to show that the spread of pathological tau can be impeded in rodent models: passive immunotherapy with novel antibodies and an intravenously delivered vectorized novel antibody using a blood-brain-barrier penetrating AAV capsid.
  • Although current therapies are limited to symptom management and have a modest impact1, investigational therapeutics designed to disrupt the propagation of tau pathology may hold promise in the treatment of tauopathies.
  • The Voyager team has maintained a long-standing focus on the development of novel approaches to disrupt the progression of tau pathology believed to be central to multiple neurodegenerative diseases, said Todd Carter, Ph.D., Senior Vice President of Research at Voyager.
  • Selected antibodies were demonstrated to block the seeding/propagation of filamentous tau in a P301S seeding-propagation tauopathy mouse model and demonstrated substantial reduction of induced tau pathology.

Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting

Retrieved on: 
Giovedì, Luglio 28, 2022
Stem Cells, Biotechnology, FDA, Health, Pharmaceutical, Neurology, Mental Health, Research, Genetics, Science, Clinical Trials, MRI, Patient, Gantenerumab, Neuron, ADAD, Brain, OLE, APOE, Dementia, Multiple sclerosis, Cerebrospinal fluid, Physician, Immunoglobulin G, Neuroscience, Microglia, Research, Biomarker, Road, Alzheimer's disease, Hoffmann-La Roche, Fortis Healthcare, Risk, Marguerite, Amyloid, Tau, Safety, Crenezumab, Scarlet, PET, Cell damage, Roche, CSF, Machine learning, Biotechnology, Disease, Neurotoxicity, Science, Neurodegeneration, Lists of diseases, Stroke, Autism, Hope, Health, Magnetic resonance imaging, ARIA, II, Tauopathy, Medical imaging, Vaccine, Pharmaceutical industry, Genentech

Today, the companies Alzheimers portfolio spans investigational medicines for different targets, types and stages of the disease.

Key Points: 
  • Today, the companies Alzheimers portfolio spans investigational medicines for different targets, types and stages of the disease.
  • GRADUATION, an open-label study to evaluate the pharmacodynamic effects of once weekly administration in participants with early Alzheimers disease.
  • Unlike most Alzheimers disease prevention studies, it enrolls people up to 25 years before the disease has started in the brain.
  • Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, stroke, Alzheimers disease, Parkinsons disease and autism spectrum disorder.

Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company

Retrieved on: 
Mercoledì, Luglio 20, 2022
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research strategies of election campaign communication research, Strategic planning, CFO, Pfizer, Magellan Development Group, Twitter, Neurodegeneration, Palsy, Development, Frontotemporal dementia, Outline of health sciences, COO, Senior, LinkedIn, Acceleration, Head, MTV Europe Music Award for Best Africa, Middle East and India Act, Therapy, New product development, Albert Einstein College of Medicine, Leadership, Tauopathy, Pharmaceutical industry, Management, Rutgers University, Economics

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimers diseases, today announced several organizational changes reflecting the transition to a clinical-stage pharmaceutical company.

Key Points: 
  • Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimers diseases, today announced several organizational changes reflecting the transition to a clinical-stage pharmaceutical company.
  • As part of this reorganization, William Erhardt, M.D., previously Chief Medical Officer of Oligomerix, will become President, Head of Development & Operations.
  • Additionally, Robert Foerster, CFO, takes on the additional role of Chief Operating Officer in recognition of his very significant contributions to Oligomerix.
  • I am very pleased to take on the role as President, Head of Development & Operations of Oligomerix as we transition from discovery research into a clinically focused biopharmaceutical company.

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

Retrieved on: 
Giovedì, Giugno 9, 2022
FTD, Human, Frontotemporal dementia, Use, Company, Cognition, Stroke, APP, Toxicity, Patent, LinkedIn, Pharmacokinetics, Annual report, Forward-looking statement, CEO, Neurodegeneration, Neuron, Tauopathy, Security (finance), Inflammation, U.S. Securities and Exchange Commission, Parkinson's disease, Neurotoxicity, Intellectual property, Bio, Risk, Brain, Memory, Patient, AD, CTE, NYSE, Alpha-synuclein, Fungus, Twitter, Drug discovery, Patent Cooperation Treaty, Alzheimer's disease, Infection, PD, Gian Maria Annovi, Parasitism, Axonal transport, Chronic traumatic encephalopathy, Protein, Pharmaceutical industry

BERWYN, Pa., June 9, 2022 /PRNewswire/ -- Annovis Bio (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that the company submitted an international patent application under the Patent Cooperation Treaty for its drug platform buntanetap. The patent claims a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans.

Key Points: 
  • The patent claims a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans.
  • Neurotoxic protein levels, such as APP/Abeta, alpha-synuclein and tau/phospho-tau,are high in both chronic and acute brain injuries.
  • Because infections, whether viral, bacterial, or fungal, also cause an increase in these neurotoxic proteins, buntanetap has the potential to protect the brain from damage caused by infections.
  • For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter .

Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development

Retrieved on: 
Giovedì, Giugno 2, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acceleration, Frontotemporal dementia, Albert Einstein College of Medicine, Company, Series, Research, MBA, LinkedIn, CEO, Neurodegeneration, Outline of health sciences, Tauopathy, NIH, Therapy, Solution, Palsy, Dementia, Twitter, Pharmaceutical industry

Funding from the Series B will allow Oligomerix to accelerate its transition into Phase 1 human clinical development planned for early 3Q 2022.

Key Points: 
  • Funding from the Series B will allow Oligomerix to accelerate its transition into Phase 1 human clinical development planned for early 3Q 2022.
  • Over the last several years, Oligomerix intentionally sought support through non-dilutive NIH-sponsored grants and other small rounds of funding to finance the company.
  • However, we are now actively broadening our search for additional investor funding to support our continuing clinical program, said James Moe, Ph.D., MBA, President and CEO of Oligomerix.
  • Preclinical safety studies are completed and Phase 1a clinical studies are planned to initiate in the third quarter of 2022.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Giovedì, Giugno 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas  , June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Giovedì, Giugno 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.